Ahmed Valve Implantation with Adjunctive Mitomycin C and 5-Fluorouracil: Long-term Outcomes
Accepted 4 April 2008. published online 16 May 2008.
Refers to article:
A Modified Technique of Ahmed Glaucoma Valve Implantation with Adjunctive Use of Antifibrotic Agents
, 20 May 2008
Simon K. Law
American Journal of Ophthalmology
August 2008 (Vol. 146, Issue 2, Pages 156-158) Full Text |
Full-Text PDF (51 KB)
Purpose
To evaluate long-term outcomes after Ahmed valve implantation in patients with glaucoma when using adjunctive intraoperative mitomycin C (MMC) and postoperative 5-fluorouracil (5-FU).
Design
Retrospective, interventional, consecutive case series.
Methods
A consecutive series of eyes undergoing Ahmed valve implantation, either alone (AHMED eyes) or in combination with cataract surgery (AHMED+PHACO), using both intraoperative MMC and postoperative 5-FU were evaluated. Failure was defined as the first occurrence of any of the following: 1) the first of three consecutive visits where intraocular pressure (IOP) was >18 mm Hg or <20% IOP reduction from baseline and the final number of topical medications was not reduced by at least two from baseline, 2) the need for additional surgery, or 3) the development of serious complications.
Results
A total of 130 eyes underwent Ahmed valve implantation with intraoperative exposure to 0.5 mg/ml MMC (median time: eight minutes; range, four to 10) and postoperative subconjunctival injections of 5 mg of 5-FU (median: five injections; range, zero to nine). Kaplan-Meier estimates of the cumulative probability of valve success and confidence interval (CI) at the sixth follow-up year were 0.72 (95% CI, 0.59 to 0.82) for AHMED eyes (n = 88), 0.84 (95% CI, 0.65 to 0.93) for AHMED+PHACO eyes (n = 42). A median of two fewer medications were required relative to baseline for both AHMED and AHMED+PHACO eyes.
Conclusions
The adjunctive use of both intraoperative MMC and postoperative 5-FU with Ahmed valve implantation results in high success rates. IOP was well controlled in the majority of patients within the six-year postoperative period.
Department of Ophthalmology, Glaucoma Research Laboratory, University of California, San Francisco, San Francisco, California.
Inquiries to Jorge A. Alvarado, Department of Ophthalmology, University of California, San Francisco, 10 Koret Way, San Francisco, CA 94143
ABSTRACT